Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome
Lanlan Zhou(Brown University), Xueyi Pan(Army Medical University), Yuemei Yuan(First Affiliated Hospital of Guangdong Pharmaceutical University), Shiqiu Qiu(First Affiliated Hospital of Guangdong Pharmaceutical University), Chaolun Chen(First Affiliated Hospital of Guangdong Pharmaceutical University), Hong Wang(Nanjing Forestry University), Yanan Liu(Jiangsu Institute of Meteorological Sciences), Mingjie Li(Shenyang Pharmaceutical University), Shimei Yang(First Affiliated Hospital of Guangdong Pharmaceutical University), Hanling Zhang(First Affiliated Hospital of Guangdong Pharmaceutical University), Zhenzhen Wen(Sir Run Run Shaw Hospital), Yanmin Gao(Shanghai East Hospital), Wenbin Zeng(First Affiliated Hospital of Guangdong Pharmaceutical University), Qiuhua Zhu(First Affiliated Hospital of Guangdong Pharmaceutical University)
Cited by 47
Related Papers
Superwetting Porous Materials for Wastewater Treatment: from Immiscible Oil/Water Mixture to Emulsion Separation
|Advanced Materials Interfaces|2017|287
Serum <scp>B</scp>‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
|British Journal of Haematology|2012|277
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease
|Molecular Neurodegeneration|2020|220
Sialic acid (SA)-modified selenium nanoparticles coated with a high blood–brain barrier permeability peptide-B6 peptide for potential use in Alzheimer’s disease
|Acta Biomaterialia|2015|193
Degradation of aniline in aqueous solution using non-thermal plasma generated in microbubbles
|Chemical Engineering Journal|2018|185